Increased long term mortality associated with rash after early measles vaccination in rural Senegal

Pediatric Infectious Disease Journal

Volumn 18, Issue 1, 1999, Pages 48-52

  Seng, Rémonie ^b   Samb, Badara ^a,b   Simondon, François ^a,c   Cissé, Badara ^a   Soumaré, Masserigne ^d   Jensen, Henrik ^e   Bennett, John ^f   Whittle, Hilton ^g   Aaby, Peter ^a,e  

^a INSTITUT DE RECHERCHE POUR LE DÉVELOPPEMENT   (Senegal)

^b INSERM   (France)

^c INSTITUT DE RECHERCHE POUR LE DÉVELOPPEMENT   (France)

^d UNIVERSITÉ CHEIKH ANTA DIOP   (Senegal)

^e DEPARTMENT OF EPIDEMIOLOGY RESEARCH   (Denmark)

^f Task Force Child Survival and Devmt   (United States)

^g MEDICAL RESEARCH COUNCIL LABORATORIES   (Gambia)

Author keywords

Africa; Measles vaccination; Mortality; Side effects

Indexed keywords

MEASLES VACCINE;

ANTIBODY TITER; ARTICLE; CHILD; DIARRHEA; FEMALE; FEVER; HUMAN; IMMUNIZATION; IMMUNOGENICITY; MAJOR CLINICAL STUDY; MALE; MEASLES; MEASLES VACCINATION; MORTALITY; PRIORITY JOURNAL; RASH; RURAL AREA; SENEGAL;

EID: 0032933751     PISSN: 08913668     EISSN: None     Source Type: Journal    
DOI: 10.1097/00006454-199901000-00012     Document Type: Article

References (28)

1. Whittle H, Hanlon P, O'Neill K, et al. Trial of high-dose Edmonston-Zagreb measles vaccine in The Gambia: antibody response and side-effects. Lancet 1988;2:811-14.
2. Tidjani O, Grunitsky B, Guerin N, et al. Serological effects of Edmonston-Zagreb, Schwarz, and AIK-C measles vaccine strains given at ages 4-5 or 8-10 months. Lancet 1989;2: 1357-60.
3. Markowitz LE, Sepulveda J, Diaz-Ortega JL, et al. Immunization of six months old infants with different doses of Edmonston-Zagreb and Schwarz measles vaccines. N Engl J Med 1990;322:580-7.
4. Whittle HC, Campbell H, Rahman S, Armstrong JRM. Antibody persistence in Gambian children after high-dose Edmonston-Zagreb measles vaccine. Lancet 1990;336:1046-8.
5. Aaby P, Jensen TG, Hansen HL, et al. Trial of high-dose Edmonston-Zagreb measles vaccine in Guinea-Bissau: protective efficacy. Lancet 1988;2:809-11.
6. Aaby P, Clements J. Measles immunization research: a review. Bull WHO 1989;67:443-8.
7. Garenne M, Aaby P. Pattern of exposure and measles mortality in Senegal. J Infect Dis 1990;161:1088-94.
8. Aaby P, Bukh J, Hoff G, et al. High measles mortality in infancy related to intensity of exposure. J Pediatr 1986;109:40-4.
9. Aaby P, Bukh J, Kronborg D, Lisse IM, da Silva MC. Delayed excess mortality after exposure to measles during the first six months of life. Am J Epidemiol 1990;132:211-19.
10. Expanded Programme on Immunization. Global Advisory Group. WHO Weekly Epidemiol Rec 1990;65:6-11.
11. Aaby P, Knudsen K, Whittle H, et al. Long-term survival after Edmonston-Zagreb measles vaccination in Guinea-Bissau: increased female mortality. J Pediatr 1993;122: 904-8.
12. Aaby P, Samb B, Simondon F, et al. Sex specific differences in mortality after high titre measles immunization in rural Senegal. Bull WHO 1994;72:761-70.
13. Holt EA, Moulton LH, Siberry GK, Halsey NA. Differential mortality by measles vaccine, titre and sex. J Infect Dis 1993;168:1087-96.
14. Expanded Programme on Immunization. Safety of high titre measles vaccines. Weekly Epidemiol Rec 1992;67:357-61.
15. Lisse IM, Aaby P, Whittle H, Knudsen K, Andersen H. Long term impact of high-titer measles vaccine on T-cell subsets. Pediatr Infect Dis J 1994;13:109-12.
16. Samb B, Whittle H, Aaby P, et al. No evidence of long term immunosuppression after high titer Edmonston-Zagreb measles vaccination in Senegal. J Infect Dis 1995;171:506-8.
17. Léon ME, Ward B, Kanashiro R, et al. Immunologic parameters 2 years after high titer measles immunization in Peruvian children. J Infect Dis 1993;168:1097-104.
18. Becker C, Chahnazarian A, Delaunay V, et al. Population et santé à Niakhar, 1984-1991. Dakar, Senegal: ORSTOM, 1992.
19. Garenne M, Maire B, Fontaine O, Dieng K, Briend A. Risques de décès associés á différents états nutritionnels chez l'enfant d'âge préscolaire. Dakar, Senegal: ORSTOM, 1987.
20. Samb B, Aaby P, Whittle H, et al. Protective efficacy of high titre measles vaccines administered from the age of 5 months. Trans Roy Soc Trop Med Hyg 1993;87:697-701.
21. Oakes D. Analysis of survival data. London: Chapman and Hall, 1984.
22. Kimura A, Tosake K, Makao I. Measles rash: 1. Light and electron microscopic study of eruptions. Arch Virol 1975;47: 295-307.
23. Kempe CH, Fulgitini VA. The pathogenesis of measles virus infection. Arch Ges Virusforsch 1965;16:103.
24. Whittle HC, Mee J, Werblinska A, Yakula C, Onuora A, Gomwalk N. Immunity to measles in malnourished children. Clin Exp Immunol 1980;42:144-51.
25. Burnet FM. Measles as an index of immunological function. Lancet 1968;2:6:10-12.
26. Böttiger M, Heller L, Kamensky P, Svanberg B. Conversion rates and side effects following vaccination with three different batches of the "Schwarz" measles strain. J Biol Stand 1973;1:225-31.
27. Aaby P, Samb B, Simondon F, Coll Seck AM, Knudsen K, Whittle H. Non-specific beneficial effect of measles immunization: analysis of mortality studies from developing countries. Br Med J 1995;311:481-5.
28. Aaby P, Samb B, Andersen M, Simondon F. No long-term excess mortality after measles infection: a community study from Senegal. Am J Epidemiol 1996;143:1035-41.